INTERMACS分级与门诊晚期心衰患者预后:REVIVAL注册研究
REVIVAL前瞻性观察研究纳入21个中心的400例门诊晚期心衰患者,评估INTERMACS分级与预后关系。结果显示较低INTERMACS分级与更多住院、衰弱、功能受损及12个月复合终点(死亡、持久MCS或紧急移植)风险升高相关(P=0.004)。
要点
- 门诊晚期心衰患者中INTERMACS 4-7级分布为8%、21%、39%、32%。
- 较低INTERMACS分级与更多住院、衰弱及功能容量受损相关。
- 12个月复合终点风险随分级降低而升高(P=0.004)。
核心结论
- 在门诊晚期心衰患者中,较低INTERMACS分级与多维度心衰负担加重及持久MCS、紧急移植或死亡的复合风险升高相关。
研究设计与样本
- REVIVAL为前瞻性观察研究,纳入21个MCS和心脏移植中心的400例门诊患者。
- 入组标准为NYHA II-IV级症状且优化药物和电治疗后,近期心衰住院、已列入心脏移植名单或高神经激素激活证据。
主要发现
- 队列包括INTERMACS 4级33例(8%)、5级83例(21%)、6级155例(39%)、7级129例(32%)。
- 各INTERMACS分级间年龄、性别、射血分数、血压或指南导向药物治疗使用无差异。
- 较低INTERMACS分级与更多住院、更严重衰弱、更差功能容量和生活质量相关。
- 12个月死亡、持久MCS或紧急移植复合终点在INTERMACS 4、5、6、7级中分别发生于39%、27%、24%、14%的受试者(p=0.004)。
临床怎么用
- INTERMACS分级可用于门诊晚期心衰患者的风险分层和高级治疗分诊评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Ambulatory patients with advanced heart failure (HF) are often considered for advanced therapies, including durable mechanical circulatory support (MCS). The Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) profiles are a commonly used descriptor of disease severity in patients receiving MCS devices, but their role in defining the prognosis of ambulatory patients is less well established, especially for Profiles 6 and 7. METHODS: Registry Evaluation of Vital Information on Ventricular Assist Devices in Ambulatory Life is a prospective observational study of 400 outpatients from 21 MCS and cardiac transplant centers. Eligible patients had New York Heart Association Class II to IV symptoms despite optimal medical and electrical therapies with a recent HF hospitalization, heart transplant listing, or evidence of high neurohormonal activation. RESULTS: The cohort included 33 INTERMACS Profile 4 (8%), 83 Profile 5 (21%), 155 Profile 6 (39%), and 129 Profile 7 (32%). Across INTERMACS profiles, there were no differences in age, gender, ejection fraction, blood pressure, or use of guideline-directed medical therapy. A lower INTERMACS profile was associated with more hospitalizations, greater frailty, and more impaired functional capacity and quality of life. The composite end point of death, durable MCS, or urgent transplant at 12 months occurred in 39%, 27%, 24%, and 14% subjects with INTERMACS Profiles 4, 5, 6, and 7, respectively (p = 0.004). CONCLUSIONS: Among ambulatory patients with advanced HF, a lower INTERMACS profile was associated with a greater burden of HF across multiple dimensions and a higher composite risk of durable MCS, urgent transplant, or death. These profiles may assist in risk assessment and triaging ambulatory patients to advanced therapies.
引用
- Kittleson MM, Shah P, Lala A, et al. INTERMACS profiles and outcomes of ambulatory advanced heart failure patients: A report from the REVIVAL Registry. J Heart Lung Transplant. 2019. PMID: 31522912. doi:10.1016/j.healun.2019.08.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。